Novartis AG

World Rank (Aug-2026)

61

Market Cap (Aug-2026)

286.780 Billion USD

World Rank (Jan-05-2024)

45

Market Cap (Jan-05-2024)

216.513 Billion USD

World Rank (Jul-30-2023)

45

Market Cap (Jul-30-2023)

220.820 Billion USD

World Rank (Jan-07-2022)

61

Market Cap (Jan-07-2022)

201.260 Billion USD

World Rank (Jan-01-2021)

39

Market Cap (Jan-01-2021)

217.770 Billion USD

Headquarters Country

Switzerland

Top Healthcare Companies in Europe

Top Technology Companies in Europe

Top Pharmaceutical Companies in Europe

Nasdaq / NYSE Code

NVS

CEO

Vasant Narasimhan

Chairman

Joerg Reinhardt

Founders

Alexander Clavel

Johann Rudolf Geigy-Merian

Employee Count

101,703

Employee Count as of Date

As on 2022

Headquarters City/State

Basel

World Region

Europe

World Subregion

Western Europe

Annual Revenue in USD

56,674 Million USD

Annual Operating Income in USD

17,644 Million USD

Annual Net Income in USD

13,984 Million USD

Annual Results for Period Ending

For year ending December-2025

Total Assets in USD

110,949 Million USD

Total Liabilities in USD

64,400 Million USD

Total Equity in USD

46,549 Million USD

Balance Sheet for Period Ending

As of December-2025

Business Sector

Company Website

Novartis - Healthcare and Pharmaceutical Companies in World

Wikipedia

Yahoo

Yahoo @ NYSE

Facebook

Company Profile

Novartis is Switzerland based Multi-National Healthcare and Pharmaceutical company. Novartis Company focus on patented medicines, generic medicines and eye care – segments where they have the innovation power and global scale necessary to compete effectively. At the same time, Novartis is expanding their presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high- quality medicines and healthcare.

Facts About Company

Novartis annual revenue was 51.83 billion USD for year ending Dec-2022 and annual operating profit was 9.19 billion USD and annual net income was 6.95 billion USD for the same period.

Novartis had over 101,703 employees worldwide as on 2022.

Split of Novartis annual revenue 50,545 billion USD for year ending Dec-2022, Innovative Medicines business segment earned 41,296 million USD revenue and Sandoz business segment earned 9,249 million USD revenue.

Within the Innovative Medicines business segment:
Cardiovascular division earned 4,756 million USD revenue.
Immunology division earned 7,287 million USD revenue.
Neuroscience division earned 5,051 million USD revenue.
Solid Tumors division earned 4,723 million USD revenue.
Hematology division earned 6,452 million USD revenue.
Other Promoted Brands division earned 3,127 million USD revenue.
Established Brands division earned 9,900 million USD revenue.

Annual Results Summary

Novartis AG - Yearly Revenues and Profits - in Million USD:

Year	Total Annual Revenue(USD mm)	Gross Profit (USD mm)	Operating Profit (USD mm)	Net Income (USD mm)
2025	54,532.00	42,975.00	17,644.00	13,967.00
2024	50,317.00	38,895.00	14,544.00	11,939.00
2023	45,440.00	34,188.00	9,769.00	14,854.00
2022	50,545.00	36,342.00	9,197.00	6,955.00
2021	51,626.00	37,010.00	11,689.00	24,018.00
2020	48,659.00	34,777.00	10,152.00	8,071.00
2019	47,445.00	34,252.00	9,086.00	11,737.00
2018	51,900.00	34,759.00	8,169.00	12,614.00
2017	49,109.00	32,960.00	8,629.00	7,703.00
2016	48,518.00	31,916.00	8,268.00	6,698.00

Balance Sheet Summary

Novartis AG - Balance Sheet Summary - in Million USD:

Year	Total Assets (USD mm)	Total Liabilities (USD mm)	Total Equity (USD mm)
2025	110,949.00	64,400.00	46,549.00
2024	102,246.00	58,120.00	44,126.00
2023	99,945.00	53,195.00	46,750.00
2022	117,453.00	58,030.00	59,423.00
2021	131,795.00	63,973.00	67,822.00
2020	132,059.00	75,393.00	56,666.00
2019	118,370.00	62,819.00	55,551.00
2018	145,563.00	66,871.00	78,692.00
2017	133,079.00	58,852.00	74,227.00
2016	130,124.00	55,233.00	74,891.00